Promis Neurosciences
In the quarter to June 2026, EPS grew 82.3% and free cash flow fell 169.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PMN
Promis Neurosciences (PMN) EV/Sales
As of 16 October 2026, Promis Neurosciences (PMN) trades at a EV/Sales of 11,382×. Over the past ten years it has ranged from −413× (December 2023) to 225,458× (March 2019); the current reading is higher than 48% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 10,044× | (66.06%) |
| FY2019 | 29,590× | (80.73%) |
| FY2018 | 153,548× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 10,044× | (55.07%) |
| Jun 2020 | 22,357× | (24.45%) |
| Dec 2019 | 29,590× | (74.73%) |
| Sep 2019 | 117,101× | 3.23% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| PTHS Pelthos Therapeutics Inc. compare | 2.7× |
| NTRB Nutriband Inc. compare | 44.7× |
| CRDF Cardiff Oncology, Inc. compare | 57.3× |
| PMN Promis Neurosciences | 11,382× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)